All Mismarketing articles
-
BusinessCelgene pays $280m to settle off-label marketing lawsuit
Whistleblower case relating to cancer prescriptions
-
BusinessLies and deception see Astellas UK suspended by trade body
Company promoted drugs inappropriately and misled regulators in the resulting investigation
-
Business
Takeda offers $2.4bn to settle diabetes litigation
Aims to settle multiple outstanding lawsuits relating to Actos (pioglitazone) and bladder cancer
-
Business
Drug giants settle mismarketing lawsuits
Pfizer and GSK settle claims over promoting drugs for unapproved uses in the US
-
BusinessMissing safety risk emails draw $9bn Actos fine
Judge finds absence of Takeda documentation in bladder cancer case ‘disturbing’
-
Business
$1.2bn J&J deceptive marketing fine overturned
Supreme court reverses decision to fine firm over Risperdal promotion
-
Business
Novartis in the spotlight in mis-selling investigations
Crackdown on pharma marketing continues with US and Japanese cases
-
-
BusinessMis-selling lands J&J with $2.2bn fine
Company found guilty of promoting three drugs for unapproved uses
-
Business
Big data to sniff out drug marketing fraud
US Food and Drug Administration wants to track promotional spending to spot off-label marketing
-
Business$3bn GSK fine sets new industry record
The fine relates to off label marketing and is the largest payment of its kind ever made by a drug company